Tower Research Capital (TRC)’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-13,870
| Closed | -$3.2K | – | 6097 |
|
|
2024
Q3 | $3.2K | Buy |
13,870
+1,218
| +10% | +$447 | ﹤0.01% | 4886 |
|
|
2024
Q2 | $6.88K | Buy |
12,652
+3,763
| +42% | +$2.97K | ﹤0.01% | 4528 |
|
|
2024
Q1 | $9.07K | Sell |
8,889
-5,109
| -36% | -$3.73K | ﹤0.01% | 3903 |
|
|
2023
Q4 | $7.98K | Buy |
13,998
+8,939
| +177% | +$5.49K | ﹤0.01% | 4557 |
|
|
2023
Q3 | $5.26K | Buy |
5,059
+17
| +0.3% | +$23 | ﹤0.01% | 4743 |
|
|
2023
Q2 | $7.11K | Sell |
5,042
-10,557
| -68% | -$15.1K | ﹤0.01% | 4618 |
|
|
2023
Q1 | $25K | Buy |
15,599
+361
| +2% | +$656 | ﹤0.01% | 3222 |
|
|
2022
Q4 | $22K | Buy |
15,238
+13,093
| +610% | +$38.2K | ﹤0.01% | 3064 |
|
|
2022
Q3 | $9K | Buy |
2,145
+1,237
| +136% | +$5.24K | ﹤0.01% | 4713 |
|
|
2022
Q2 | $4K | Sell |
908
-965
| -52% | -$2.75K | ﹤0.01% | 5276 |
|
|
2022
Q1 | $9K | Sell |
1,873
-4,518
| -71% | -$13.6K | ﹤0.01% | 4510 |
|
|
2021
Q4 | $23K | Buy |
6,391
+5,464
| +589% | +$29.2K | ﹤0.01% | 3532 |
|
|
2021
Q3 | $7K | Buy |
927
+286
| +45% | +$2.82K | ﹤0.01% | 4689 |
|
|
2021
Q2 | $7K | Sell |
641
-5,745
| -90% | -$57.6K | ﹤0.01% | 4575 |
|
|
2021
Q1 | $59K | Buy |
6,386
+5,859
| +1,112% | +$61K | ﹤0.01% | 2985 |
|
|
2020
Q4 | $4K | Buy |
527
+312
| +145% | +$1.63K | ﹤0.01% | 4737 |
|
|
2020
Q3 | $1K | Sell |
215
-2,033
| -90% | -$17.8K | ﹤0.01% | 4746 |
|
|
2020
Q2 | $21K | Buy |
+2,248
| New | +$33.9K | ﹤0.01% | 3659 |
|
|
2018
Q4 | – | Sell |
-366
| Closed | -$26K | – | 4468 |
|
|
2018
Q3 | $26K | Buy |
366
+300
| +455% | +$22.8K | ﹤0.01% | 2177 |
|
|
2018
Q2 | $5K | Buy |
+66
| New | +$5.88K | ﹤0.01% | 3083 |
|
|
2017
Q4 | – | Sell |
-241
| Closed | -$16K | – | 4122 |
|
|
2017
Q3 | $16K | Buy |
+241
| New | +$19.7K | ﹤0.01% | 2868 |
|
|
2017
Q2 | – | Sell |
-66
| Closed | -$10K | – | 3580 |
|
|
2017
Q1 | $10K | Sell |
66
-148
| -69% | -$21.2K | ﹤0.01% | 1793 |
|
|
2016
Q4 | $27K | Buy |
+214
| New | +$29.8K | ﹤0.01% | 1893 |
|
|
2016
Q2 | – | Sell |
-14
| Closed | -$2K | – | 5079 |
|
|
2016
Q1 | $2K | Sell |
14
-19
| -58% | -$2.88K | ﹤0.01% | 3465 |
|
|
2015
Q4 | $6K | Buy |
+33
| New | +$6.17K | ﹤0.01% | 2842 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 4914 |
|
|
2015
Q2 | – | Sell |
-10
| Closed | -$5.31K | – | 5143 |
|
|
2015
Q1 | $5K | Buy |
+10
| New | +$5.04K | ﹤0.01% | 3282 |
|
|
2014
Q4 | – | Sell |
-12
| Closed | -$18K | – | 4802 |
|
|
2014
Q3 | $18K | Buy |
+12
| New | +$17.4K | ﹤0.01% | 2399 |
|
|
2014
Q2 | – | Sell |
-5
| Closed | -$5.8K | – | 4738 |
|
|
2014
Q1 | $7K | Buy |
5
+3
| +150% | +$3.49K | ﹤0.01% | 3004 |
|
|
2013
Q4 | $2K | Sell |
2
-6
| -75% | -$6.2K | ﹤0.01% | 4065 |
|
|
2013
Q3 | $8K | Buy |
8
+3
| +60% | +$3.21K | ﹤0.01% | 3378 |
|
|
2013
Q2 | $5K | Buy |
+5
| New | +$5.57K | ﹤0.01% | 2972 |
|
Other funds holding VIRX
ACM
VF
HF
Tower Research Capital (TRC)'s VIRX Position: Q4 2024 in Review
Tower Research Capital (TRC) sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2024, closing a stake of 13,870 shares — an estimated $3.2K sold.
Tower Research Capital (TRC) first reported a position in VIRX in Q2 2013 and held it in 31 quarters. The position peaked at $59K in Q1 2021. 32 funds tracked by Wall St. Rank hold VIRX as of Q4 2024.
- Tower Research Capital (TRC) reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Tower Research Capital (TRC) sold 13,870 Viracta Therapeutics, Inc. Common Stock shares in Q4 2024, an estimated $3.2K.
- Tower Research Capital (TRC) first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 31 quarters.
- Tower Research Capital (TRC)'s Viracta Therapeutics, Inc. Common Stock position peaked at $59K in Q1 2021.
- 32 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2024.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2024, filed 13 Feb 2025.